ClinicalTrials.gg
Not yet recruitingNCT07658482Updated Aug 20, 2026

A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers

A Phase 1 interventional study of ZL-1503 and ZL-1503 in Healthy Volunteers, sponsored by Zai Lab (Shanghai) Co., Ltd.. Not yet recruiting at 1 site in New Zealand. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Zai Lab (Shanghai) Co., Ltd. (part of Zai Lab Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a phase 1, single dose, randomized, open-label, parallel-group study to evaluate the pharmacokinetics (PK), safety, tolerability and immunogenicity of ZL-1503 and to explore its PD biomarkers following a single subcutaneous (SC) or intravenous (IV) administration in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
03

In context

Lead sponsor

Zai Lab (Shanghai) Co., Ltd. is the lead sponsor of 25 studies on the registry; 8 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female volunteers, 18-65 years of age
  • (BMI) between ≥ 18.5 and \< 32.5 kg/m2
  • Negative pregnancy tests for women of .

Exclusion criteria

Exclusion Criteria:

  • Significant health issues, such as positive tests for (HIV), virus (HCV), surface antigen (HBsAg), active tuberculosis, immunodeficiencies or diseases.
  • History of major metabolic, liver, kidney, hematologic or other significant disorders.
  • Abnormal (ECG) findings
  • abnormal lab results, including low blood counts, or abnormal liver and kidney function.
  • History of drug abuse or addiction within 6 months prior to screening
  • Current smoker or use of any nicotine or tobacco containing products within the last 6 months prior to dosing.
  • Donated >500mL blood within 2 months of dosing.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    ZL-1503 (Intravenous Administration)

    Drug: ZL-1503

  • Experimental
    ZL-1503 (Subcutaneous Dose 1)

    Drug: ZL-1503

  • Experimental
    ZL-1503 (Subcutaneous Dose2)

    Drug: ZL-1503

Interventions

  • DrugZL-1503

    Healthy volunteers will receive a single intravenous dose of ZL-1503.

  • DrugZL-1503

    Healthy volunteers will receive a single subcutaneous administration at Dose 1.

  • DrugZL-1503

    Healthy volunteers will receive a single subcutaneous administration at Dose 2.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax)

    Time frame: From Predose to Day 337

  2. Time to maximum concentration (Tmax)

    Time frame: From Predose to Day 337

  3. Area under the plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast)

    Time frame: From Predose to Day 337

  4. Area under the plasma concentration-time curve from time zero to infinity (AUCinf)

    Time frame: From Predose to Day 337

  5. Apparent terminal elimination half-life (t1/2)

    Time frame: From Predose to Day 337

  6. Apparent total body clearance (CL/F)

    Time frame: From Predose to Day 337

  7. Apparent volume of distribution (Vz/F)

    Time frame: From Predose to Day 337

  8. Steady State Volume of distribution (Vss IV)

    Time frame: From Predose to Day 337

  9. Total Body Clearance (CL IV)

    Time frame: From Predose to Day 337

  10. Absolute bioavailability (F)

    Time frame: From Predose to Day 337

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Feb 2027, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2026
First posted
Jun 22, 2026
StartEst.
Sep 3, 2026
Primary completionEst.
Feb 6, 2027
CompletionEst.
Nov 10, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07658482
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Sep 3, 2026 (estimated)
Primary completion
Feb 6, 2027 (estimated)
Completion
Nov 10, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

ZaiLab Medical Director
Contact
ZL-1503-002_StudyTeam@zailaboratory.com
+86 021-61632588

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion